Re-differentiating therapy of radioiodine-refractory differentiated thyroid cancer
10.3969/j.issn.1007-3969.2016.01.006
- VernacularTitle:131I难治性分化型甲状腺癌的再分化治疗
- Author:
Lingxiao CHENG
;
Libo CHEN
- Publication Type:Journal Article
- Keywords:
Thyroid cancer;
Re-differentiating therapy;
Targeted agents;
131I
- From:
China Oncology
2016;(1):35-42
- CountryChina
- Language:Chinese
-
Abstract:
Clinical management of radioiodine-refractory differentiated thyroid cancer (RR-DTC) is extremely diffcult. Re-differentiation compounds, such as retinoids, peroxisome proliferator-activated receptor (PPAR) agonists, DNA methyltransferase inhibitors and histone deacetylase inhibitors, have been used in trials to increase iodine uptake in RR-DTC. However, data on these drugs failed to meet the initial high expectations. In recent years, targeted agents have been increasingly used in pre-clinical and clinical studies to induce re-differentiation and mediate131I therapy, and the outcomes are encouraging.
